Every 10-Q that CNS Pharmaceuticals, Inc. (CNSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNSP filings page.
CNS Pharmaceuticals, Inc. reported interim results for the three and six months ended June 30, 2026, reflecting its pivot to a broader pipeline strategy while remaining pre-revenue and loss-making. Total assets rose to $21.9 million from $8.6 million at year-end 2025, driven mainly by a cash balance of about $20.0 million following a May 2026 private placement and use of its at-the-market program.
The company recorded a net loss of about $2.6 million for the quarter and $7.5 million for the first half, compared with $2.4 million and $6.7 million in the prior-year periods, as research and development and general and administrative expenses both increased. As of June 30, 2026, accumulated deficit reached $107.8 million, but management states existing cash plus net proceeds from recent financings are expected to fund planned operations for more than twelve months from issuance of these financial statements.
CNS completed a $22.5 million gross private placement, issuing 650,000 common shares and pre-funded warrants for 9,143,479 shares, and sold additional stock via its AGP ATM program. It reported material weaknesses in internal control over financial reporting, including segregation-of-duties limitations and reliance on a contract research organization, and disclosed these controls remain ineffective as of June 30, 2026.
CNS Pharmaceuticals reported a wider quarterly loss as it pivots strategy but shored up liquidity after quarter-end. For the three months ended March 31, 2026, the company recorded a net loss of about $4.9 million, compared with $4.3 million a year earlier, driven mainly by higher research and development and professional expenses.
Cash and cash equivalents fell to $2.95 million with a working capital deficit of roughly $0.5 million as of March 31, 2026, and operating cash use rose to about $4.6 million. A May 2026 private placement then generated gross proceeds of approximately $22.5 million through common stock and pre-funded warrants, which management believes will fund operations beyond 12 months from issuance of these financial statements.
The company announced a new corporate strategy in March 2026 to pursue innovative therapies for serious diseases, moving away from a sole focus on glioblastoma and exploring out-licensing of legacy assets TPI 287 and Berubicin. CNS Pharmaceuticals continues to report a material weakness in internal control over financial reporting and is adding senior executives, including a new CEO, CFO, Chief Medical Officer and Chief Technology Officer, while providing severance to departing leaders.
CNS Pharmaceuticals reported Q3 2025 results with a narrower net loss of $3,218,481 versus $5,605,934 a year ago, as operating expenses fell to $3,253,388 from $5,628,906. General and administrative costs were $1,056,560, and research and development was $2,196,828, reflecting lower Berubicin trial spend and prior-year TPI 287 in‑licensing costs.
For the nine months, net loss improved to $9,894,762 from $11,681,435. Cash and equivalents were $9,864,087 with working capital of about $9,447,000. The company raised capital through an AGP at‑the‑market program—127,582 shares for roughly $9.0M in Q1–Q3 2025 (cumulative 210,230 shares for about $22.8M through Sept 30)—and a May 2025 public offering yielding net proceeds of about $4.5M. Management states substantial doubt about continuing as a going concern, while estimating current liquidity could extend operations into the second half of 2026, subject to clinical timelines and additional financing needs.